A concurrence of light and heavy chain deposition disease and diabetic nephropathy

Journal of the Medical Association of Thailand

Volumn 90, Issue 10, 2007, Pages 2204-2208

  Satirapoj, Bancha ^a,b   Paueksakon, Paisit ^a  

^a Phramongkutklao Hospital   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Diabetic glomerulosclerosis; Light and heavy chain deposition disease (LHCDD); Monoclonal protein; Nodular glomerulosclerosis

Indexed keywords

ENALAPRIL; FELODIPINE; FENOFIBRATE; GLIMEPIRIDE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; METFORMIN; PREDNISONE; SIMVASTATIN;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ELECTRON MICROSCOPY; FEMALE; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; HEAVY CHAIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; KIDNEY TUBULE CELL; MONOCLONAL IMMUNOGLOBULINEMIA; PROTEINURIA; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HEAVY CHAIN DISEASE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; TIME FACTORS;

EID: 35848952971     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Preud'Homme JL, Morel-Maroger L, Brouet JC, Mihaesco E, Mery JP, Seligmann M. Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol 1980; 42: 545-53.
2. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-92.
3. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999; 13: 1235-48.
4. Sakakima M, Fujigaki Y, Tsuji T, Fukasawa H, Miyaji T, Naito K, et al. High dose chemotherapy and stem cell support in a patient of light- and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med 2005; 44: 970-4.
5. Hall CL, Peat DS. Light chain deposit disease: a frequent cause of diagnostic difficulty. Nephrol Dial Transplant 2001; 16: 1939-41.
6. Buxbaum JN. Abnormal immunoglobulin synthesis in monoclonal immunoglobulin light chain and light and heavy chain deposition disease. Amyloid 2001; 8: 84-93.
7. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992; 20: 34-41.
8. Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653-6.
9. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-8.
10. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281-7.